Jubilant Biosys Limited
Jubilant Biosys Limited, a prominent player in the biopharmaceutical industry, is headquartered in India and operates extensively across North America, Europe, and Asia. Founded in 2007, the company has established itself as a leader in drug discovery and development services, catering to a diverse range of therapeutic areas including oncology, central nervous system disorders, and infectious diseases. Jubilant Biosys offers a unique blend of integrated services, from early-stage research to clinical development, which distinguishes it in a competitive market. The company’s commitment to innovation and quality has earned it a strong market position, with notable achievements in collaborations with global pharmaceutical firms. With a focus on advancing healthcare solutions, Jubilant Biosys continues to drive progress in the biopharmaceutical landscape.
DitchCarbon Score
How does Jubilant Biosys Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jubilant Biosys Limited's score of 43 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jubilant Biosys Limited, headquartered in India, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Jubilant Pharmova Limited, which may influence its climate commitments and reporting practices. As of now, Jubilant Biosys Limited has not established any documented reduction targets or climate pledges. The absence of specific initiatives or commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the lack of direct emissions data, it is essential to consider the broader context of the industry. Many companies in the pharmaceutical sector are increasingly focusing on sustainability and carbon reduction, often guided by frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, without specific commitments or data from Jubilant Biosys Limited, it is challenging to assess their position relative to industry standards. In summary, while Jubilant Biosys Limited is part of a larger corporate family that may have sustainability initiatives, the company currently lacks publicly available emissions data and defined climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jubilant Biosys Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
